Clinical Trial Update: LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients [Phase 1]

View source ↗

Summary

Phase 1 trial updating LB-100 (PP2A inhibitor) in combination with atezolizumab for metastatic microsatellite-stable colorectal cancer is recruiting at The Neth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• LB-100 (LB-100)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Metastatic Microsatellite-stable Colorectal Cancer | Phase 1 | Status: RECRUITING